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1. Introduction
1.1. Pharmacology of statin
It is known as statins a group of drugs used to lower cholesterol in patients suffering from
hypercholesterolemia and who have therefore increased risk of developing atherosclerosis and
have episodes cardiovascular disease. From the pharmacological point of view, fall within the
HMG-CoA reductase. Enzyme inhibition is precisely this which justifies the reduction of
certain fractions of cholesterol in the body and explains its importance: their positive inter‐
vention on cardiovascular risk factors, leading to numerous cardiovascular diseases, which
are the leading cause of death in the developed world [1,2]. Despite its short history (less than
forty years) are many studies that have been done on statins and hundreds of thousands of
patients who have taken these drugs. This has given rise to an extensive knowledge of the
characteristics of these drugs has led to the synthesis of new substances that improve the
properties of the above statins; in this line part of pharmaceutical research is still moving.
However, it has also given rise to broadly meet the real toxicological profile for each substance.
The phase IV studies have revealed the risks of using these substances for long periods or in
certain basal conditions, which has led, among other things, the withdrawal of any member
of the family due to their increased incidence of severe adverse reactions. Because of the
variability in origin, the pharmacokinetics of statins differ greatly, however, its pharmacody‐
namic similarities allowed their joint study group them because, in terms of mechanism of
action and effects of statins, and especially, regarding the clinical consequences of its use, there
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is an important congruence group, which has been widely studied (Table 1). All developed
statins are used orally and absorbed by this route on a variable range from 30% of lovastatin
to 35% of pravastatin, decreasing its absorption in the presence of food in the stomach.
However, the changes in peak concentrations or the respective curves of assimilation have no
impact on the final results in the modification of cholesterol levels, so it is generally advisable
to take them at any time of day and in most cases with or without food. Also, there appears to
be accumulation due to multiple doses, which is general consensus decision single dose. The
recommendations do not drink grapefruit juice while being treated with statins is due to
interference with the metabolism, not altered absorption. Generally, the bioavailability of the
statins is low, ranging from 5% of lovastatin and 17% of pravastatin. Binding to plasma proteins
is variable, but in general very high lines. Except 50% of pravastatin, all have a 95% binding
to proteins. The tissue distribution is broad, crossing the blood-brain and placental barriers,
even going to milk in lactating women. Liver specificity of these drugs is determined by its
degree of lipophilicity and by the presence of some organic anion transporter proteins that
allow more hydrophilic statins such as pravastatin and rosuvastatin, entering the hepatocyte
[3]. Moreover, some statins may inhibit P-glycoprotein (multidrug resistance protein), a carrier
protein of many drugs in the cell, which could predispose to drug interactions. [4]
PHARMACOLOGICAL CHARACTERISTICS OF STATIN
Sinvastatin Pravastatin Lovastatin Fluvastatin Atorvastatin Rosuvastatin Pitavastatin
Prodrugs YES NO YES NO NO NO NO
Food and absorptionNo influence ↓ ↑ ↓ ↓ No influence
Bioavailability ≤5% 17% ≤5% 24% 14% 20% ≥30%
Binding
to plasma proteins 94% 50% >95% 98% 98% 88% -
Crosses blood-brain
barrier YES NO YES NO NO NO YES
Metabolism CYP3A4 sulphation CYP3A4 CYP2C9 CYP3A4 CYP2C9 CYP2C9CYP2C8
Biliary excretion 60% 70% 83% 95% - 90% -
Urinary excretion 13% 20% 10% 5% <2% 30% 3%
Elimination half-life2-3h 0.8h 1-4h 2.5h 20h 20h -
Table 1. Pharmacological characteristics of statin
The metabolism of statins is liver, undergoing first pass metabolism. In most, there are
differences in the metabolism regarding sex and age, but not enough to change the doses in
the absence of other pathologies. It seems clear that are substrates of CYP450: lovastatin,
simvastatin and atorvastatin are metabolized exclusively by CYP3A4, and fluvastatin does
exclusively by 2C9. For rosuvastatin, only 10% use the CYP2C9 and 2C19. Pitavastatin has a
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low affinity for CYP2C9, so not a major metabolic pathway. Pravastatin is not metabolised by
the cytochrome, but does so by enzymes present in the cytoplasm of hepatocytes. The metab‐
olites may be hydroxylated derivatives, omega or beta-oxidized methylated glucuronide. The
pharmacological activity of the same is very variable. Thus, the range is wide, from lovastatin,
simvastatin, which are really a pharmacologically inactive lactones and performing their
pharmacological activity through its metabolites, to fluvastatin, which has virtually inactive
metabolites. For the most part, excretion in feces is due to its poor absorption. According to
each type of statins, renal excretion ranges from 2% to 20%.
Statins are inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This
enzyme catalyzes the conversion of HMG-CoA to mevalonate, which is a key metabolite in
the biosynthesis of cholesterol. Blocking occurs due to the high structural resemblance with
these drugs exhibit HMG-CoA. The affinity of the enzyme by statins is 1.000 to 10.000 times
that of the natural substrate (Figure 1).
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Figure 1. Biosynthesis of cholesterol
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The blockade of hepatic cholesterol synthesis causes an activation of the regulatory proteins
SREBP (sterol regulatory elements-binding proteins), which activate transcription of protein
and thus result in higher expression of the LDL receptor gene and increased the number of
functional receptors on hepatocytes [5]. Moreover, it has been shown that statins also produced
inhibition associated antigen-1 with the function of lymphocytes (LFA-1: lymphocyte function-
associated antigen-1) [6]. The LFA-1 is a glycoprotein integrin family expressed on the surface
of leukocytes. When the LFA-1 is activated by certain receptors, binds to the intracellular
molecule-1 adhesion (ICAM-1 or CD-54) and stimulates the extravasation of leukocytes and
activation of T lymphocytes. This means that the LFA-1 is a proinflammatory agent and its
inhibition is beneficial in conditions such as rheumatoid arthritis and rejection of homograft.
It was shown that statins and particularly, lovastatin, bind to a site of LFA-1 domain, lovastatin
currently designated site. This is the molecular mechanism by which lovastatin, simvastatin
and other statin lesser extent inhibit the LFA-1 [7]. This would be one of the anti-inflammatory
mechanisms and hence possessing antiatherogenic statins.
2. Effects of statins
The consequences of the inhibition of HMG-CoA may be grouped into two groups:
a. Derivatives of interaction on cholesterol metabolism: Lower levels of total cholesterol
and LDL, substances closely related to atherosclerosis and increased cardiovascular risk.
Density decreases LDL particles, increasing the size of these, leading to decreased
atherogenesis [8]. Apolipoprotein B also falls substantially during treatment with statins.
In addition, some statins modestly increase cHDL and reduces plasma triglycerides. As a
result of these changes, the ratio of total cholesterol to HDL cholesterol and the ratio of
LDL and HDL cholesterol are reduced. We have considered the combination of fibrate
and enhancer preventing cardiac of statins, especially having no competitive metabolism
pathways.
b. Pleiotropic effects: In addition to its effects on the lipid profile, statins have other
beneficial cardiovascular effects, especially on the arterial wall, known as pleiotropic
effects which explain the additional benefit not attributable to the reduction in cLDL
observed in many studies intervention [9].
By inhibiting HMG-CoA reductase inhibitors, statins interfere with the formation of isopre‐
noids from mevalonate. [10] Isoprenoids are molecules such as farnesyl pyrophosphate (FPP)
and geranylgeranylpyrophosphate (GGPP), derived from the metabolism of mevalonate,
which serve as lipid-tags for the posttranslational modification of a variety of proteins,
including the gamma subunit of G proteins and small GTP unidoras proteins. As a result, the
prenylation of the G proteins (Rho, Rac, Ras and Rab Rac1) is reduced. Prenylation of these
molecules is necessary for anchoring to the cell membrane and thus to exercise their mecha‐
nism of action related to migration, differentiation and cell proliferation. Generally, stimulate
and inhibit proinflammatory pathways useful mechanisms for endothelial homeostasis.
Through these potential effects on cellular proteins, statins may have a number of antiather‐
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osclerotic and antithrombotic properties, such as inhibiting the growth of smooth muscle cells,
cell adhesion, platelet activation and secretion of C-reactive protein among other. The meva‐
lonic acid, may also act directly by inhibiting the synthesis of nitric oxide (NO) in a process
dependent transferase inhibiting genilgeranil. NO is an essential molecule for proper function
and vasodilatation of endothelium. To this should be added the effects resulting from inhibi‐
tion of LFA-1, which in turn significantly impacting on endothelial function in blood vessels.
These pleiotropic effects are constant source of research, since they can extend the usage profile
of statins. Moreover, these drugs maintain and improve endothelial function to increase the
bioavailability of NO, which is synthesized by the enzyme NO synthase (eNOS). NO is the
principal regulator of the homeostasis of the arteries and endothelium-dependent vasodila‐
tion. The functions are, among others, inhibiting proinflammatory mechanisms and act as an
antioxidant on lipoproteins [12].
Statins preserve and increase the bioavailability of NO in several ways:
1. Inhibition of Rho protein increases the expression of the enzyme nitric oxide synthase.
2. Increasing the half-life of the messenger RNA of the enzyme nitric oxide synthase.
3. Reduce excess caveolin molecule that acts as an inhibitor of nitric oxide synthase enzyme.
4. Inhibit the production of superoxide.
5. To protect the NO statins decrease platelet aggregation and reducing thromboxane A2 by
platelets and thus limit the formation of unstable plaque.
6. Increasing the expression of tissue plasminogen activator and inhibit the expression of
endothelin-1, a potent vasoconstrictor with mitogenic action [12].
The hypolipidemic action itself inherently reduces oxidative stress. However, of statins have
their own antioxidant mechanisms that inhibit the production of superoxide anion radical.
Superoxide is synthesized by NADPH oxidase, an enzyme which can be activated by the action
of membrane receptor of angiotensin II, type I (R-1) receptors. Statins block the R-AT1 and also
inhibit the phosphorylation of the NADPH oxidase, inactivating it [13].
Statins also block RhoA, one of the mediators of smooth muscle proliferation. The smooth
muscle proliferation is a central phenomenon in the pathogenesis of vascular lesions, including
post-angioplasty restenosis, transplant atherosclerosis and occlusion of the coronary vein
grafts [14].
Atherosclerosis is a strong inflammatory component characterized by the presence of mono‐
cytes, macrophages and T cells in the plate. This process is induced by proinflammatory
cytokines, free radicals and NO deficiency. Statins increase the bioavailability of NO and
inhibit several proinflammatory cytokines [1].
A marker of inflammation and predictor of coronary heart disease risk is C-reactive protein
(PCR). It is considered that PCR is also proinflammatory as joining the cLDL of the atherom‐
atous, activates complement plate and induces the expression of inhibitor-1, plasminogen
activator (PAI-1), reduces the expression of eNOS and increases the expression of adhesion
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molecules [15]. Therefore, it is valid to assume that the decrease in plasma CRP levels might
be beneficial. Large studies with statins, as the AFCAPS/TexCAPS showed reduced blood PCR.
For its anti-inflammatory action, statins increase the stability of the atheromatous plaque, and
much of the reduction in coronary events attributable to the mechanism. Preclinical studies
demonstrated that statins reduce the accumulation of macrophages in the atheromatous
plaque and inhibit metalloproteinase production by activated macrophages. Metalloprotei‐
nases are capable of degrading proteins support and are therefore partly responsible for the
accident plaque with thrombus formation [16].
Clinically the effects of statins lead to a reduction in cardiovascular risk, through the following
mechanisms:
1. Directly decreasing cholesterol levels.
2. Improving endothelial function and inflammatory response.
3. Stabilizing atherosclerotic plaque.
4. Preventing thrombus formation.
Then offer recommendations for clinical practice for the treatment of hypercholesterolemia in
adults and reduce the risk of atherosclerotic cardiovascular disease, which includes coronary
heart disease, cerebrovascular disease, peripheral artery disease and other atherosclerotic
probable origin.
3. Indications of statin in clinical practice
Statins are indicated as an adjunct to diet to reduce elevated total cholesterol, LDL cholesterol,
apolipoprotein B and triglycerides; and to increase HDL cholesterol in patients with:
1. Primary hypercholesterolaemia.
2. Mixed dyslipidemia.
3. Homozygous familial hypercholesterolemia.
Also present clear indication in cardiovascular prevention [17]:
Primary prevention of coronary events: in hypercholesterolemic patients without clinical
evidence of coronary heart disease.
1. Reduce the risk of myocardial infarction.
2. Reduce the risk of myocardial revascularization procedures.
3. Reduce the risk of cardiovascular mortality with no increase in death from non-cardio‐
vascular causes.
Secondary prevention of cardiovascular events: in patients with clinical evidence of cardio‐
vascular disease.
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1. Reduce the risk of total mortality by reducing coronary death.
2. Reduce the risk of myocardial infarction.
3. Reduce the risk of myocardial revascularization procedures.
4. Reduce the risk of stroke and transient ischemic attacks (TIA).
5. Slow the progression of coronary atherosclerosis.
The latest evidence recommends an individualized approach (tailored treatment approach)
identified four risk groups associated with therapeutic strategy (Figure 2). Groups that benefit
from the use of statin therapy in moderate intensity: LDL reduction of 30-49% or high intensity,
LDL reduction of >49% both demonstrate reduction cardiovascular risk (RCV) [17].
1. Group 1: Patients with clinical cardiovascular disease (secondary prevention): high
intensity treatment with statins (<75 years) or moderate intensity (>75 years).
2. Group 2: Patients with LDL > 190 mg/dL: high intensity treatment.
3. Group 3: Diabetic patients between 40-75 years, LDL 70-189 mg/dL without cardiovascular
disease: treatment of at least moderate intensity and high intensity probably if cardiovas‐
cular estimated 10-year risk ≥7.5%.
4. Group 4: Patients without diabetes and without clinical cardiovascular disease, with LDL
between 70-189 mg / dl but with estimated 10-year risk> 7.5%: treatment of moderate to
high intensity.
3.1. Types of statin therapy
The main therapeutic strategies are (Table 2),
High-intensity
statin therapy
Moderate-intensity
statin therapy
Low-intensity
statin therapy
Daily doses lowers LDL on
average >50%
Daily dose lowers LDL on average
30-50%
Daily dose lowers LDL on average 30%
Atorvastatin 40-80 mg
Rosuvastatin 20 -40 mg
Atorvastatin 10-20 mg
Rosuvastatin 5-10 mg
Simvastatin 20-40 mg
Pravastatin 40-80 mg
Lovastatin 40 mg
Fluvastatin XL 80 mg
Fluvastatin 40 mg BID
Pitavastatin 2-4 mg
Simvastatin 10 mg
Pravastatin 10-20 mg
Lovastatin 20 mg
Fluvastatin 20-40 mg
Pitavastatin 1 mg
Table 2. Low, moderate and high-intensity statin therapy categories in treating patients with varying risks.
Statin therapy of high, moderate and low intensity according to studies is classified:
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1. Statin therapy in high-intensity studies: Atorvastatin 40-80 mg or rosuvastatin 20-40 mg.
2. Statin therapy in moderate intensity: Atorvastatin 10-20 mg, rosuvastatin 5-10 mg, simvas‐
tatin 20-40 mg (higher doses are not recommended by the incidence of adverse effects),
pravastatin 40-80 mg, lovastatin 40mg, fluvastatin XL 80 mg, *Fluvastatin 40 mg bid and
pitavastatin 2 to 4 mg.*
3. Statin therapy in low-intensity: Simvastatin 10 mg, * Pravastatin 10 mg-20 mg, lovastatin 20
mg, fluvastatin 20-40 mg and *Pitavastatin 1 mg.
* FDA approved but not tested in randomized controlled trials.
3.2. Specific risks
1. Primary prevention with LDL ≥ 160 mg/dL.
2. Genetic testing hyperlipidemias.
3. Family history of premature cardiovascular disease with onset <55years in a male first-
degree relative or <65 years female.
4. C-reactive protein levels of high sensitivity (hs-CPR) >2 mg /L,
5. Coronary artery calcium (CAC) score ≥300 Agatston units or ≥ 75th percentile for age, sex
and ethnicity.
6. Ankle-brachial index <0.9.
3.3. Treatment strategies
1. Treat for goals: It is the strategy most used in the past 15 years, but with 3 problems: Current
randomized clinical trials do not specify what the best goal. The magnitude of the further
reduction of the atherosclerotic cardiovascular disease than is obtained with a lower
cholesterol goal another is unknown. Does not account the possible adverse effects of
polypharmacy, which may be necessary to achieve a specific goal.
2. "Lower is better": This approach does not take into account the possible adverse effects of
polypharmacy with an unknown magnitude reduction in atherosclerotic cardiovascular
disease.
3. Dealing with the level of atherosclerotic cardiovascular disease (currently preferred): Consider
both benefits in reducing cardiovascular risk and adverse effects of statin therapy. Hence
the 4 groups that benefit, as previously mentioned, with the exception of use in individuals
undergoing hemodialysis or heart failure with NYHA functional class III-IV out. This
strategy is advocated today.
4. Risk throughout life: Are yet tracking data on >15 years, safety, reduction of atherosclerotic
cardiovascular disease when statins are used for periods >10 years and treatment in
individuals <40 years.
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Figure 2. Statin therapy for atherosclerotic cardiovascular disease prevention
4. Side effects of statin and clinical management
4.1. Adverse effects of statins
In general, statins are well tolerated and the dropout rate in clinical trials as a result of any
adverse effect is <10%, similar to that of patients taking placebo, and less than 1% are serious
side effects (Table 3).
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DIFFERENCES IN ADVERSE EFFECTS BETWEEN STATINS
Adverse effects Incidence
versus
placebo
Dose-response
relationship
Differences
(favor/ against)
Statistically significant
overall difference against
Abandonment
adverse impact
6% yes Simvastatin/atorvastatin
Pravastatin/atorvastatin
Pravastatin/rosuvastatin
-
Significantly
relevant myalgia
2% - - -
Relevant
significantly
increased
transaminases
1% yes Simvastatin/atorvastatin
Simvastatin/fluvastatin
Pravastatin/atorvastatin
Pravastatin/fluvastatin
Rosuvastatin/atorvastatin
Rosuvastatin/fluvastatin
Atorvastatin
Fluvastatin
Relevant
significantly
increased CPK
0.6% yes Fluvastatin/others Pitavastatin
Diabetes 9% - - -
Table 3. Differences in adverse effects between statins
1. Myotoxicity: The most serious adverse effect associated with the muscular condition,
which can range from myalgia (proximal muscle pain and/or weakness with a value of
creatine kinase (CK) normal or slightly increased) to more severe forms, such as myopathy
(pain and/or weakness over the presence of very high CK, usually >10 times normal) or
rhabdomyolysis (serious muscle condition, with muscle weakness and pain, the presence
of very high CK, myoglobinuria and renal failure) [18]. In general, the most common
disorder is myalgia without elevated CK. Special mention should be cerivastatin with‐
drawal from the market, since it is the statin showed higher number of severe myopathy.
The rate of fatal rhabdomyolysis associated with cerivastatin use at least 15 times higher
than that produced by other statins, and was associated with the use of high doses of the
drug (0.8 mg/day) or when coadministered with gemfibrozil [19].
The drugs and clinical conditions that increase the risk of myopathy are,
a. Chronic diseases (renal failure and diabetes).
b. Multiple drugs.
c. Surgical interventions.
d. High doses of statins.
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e. Statins in combination with:
• Fibrates.
• Nicotinic acid (not clearly stated)
• Cyclosporine.
• Antifungal azoles.
• Macrolide antibiotics
• Inhibitors of HIV protease.
• Verapamil.
• Amiodarone.
• Abuse of alcohol.
• Grapefruit juice (> 1/4 liter daily)
2. Hepatotoxicity: active hepatopathy or unexplained persistent elevations of serum
transaminases (hypertransaminasemia). An elevation of three times the upper limit of
normal transaminases in patients treated with statins occurs between 0.5% to 2% of cases
and is directly related to the dose [20]. Hypertransaminasemia is reversible with drug
discontinuation and progression to liver failure rarely occurs.
3. Hypersensitivity to any statin or any of the excipients of commercial presentations.
4. Dyspepsia.
5. Less common: sleep disturbances and memory, depression,....
4.2. Absolute contraindications to statins
1. Pregnancy and lactation.
2. Concomitant administration of potent inhibitors of CYP3A4 (itraconazole, ketoconazole,
protease inhibitors, erythromycin, clarithromycin, telithromycin and nefazodone) or
CYP2C9 (relative contraindication not dependent on CYP450 statins).
4.3. Relative contraindications to statins (but you can take a special medical supervision is
required)
1. Elderly (age >70 years).
2. Renal failure.
3. Uncontrolled hypothyroidism.
4. Personal or family history of hereditary muscular disorders.
5. History of muscular toxicity with a statin or fibrate.
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6. Alcoholism.
7. Concomitant weak inhibitors of CYP3A4 (Table 4)
OTHER DRUG THAT INTERACT WITH STATIN
antacids ↓  absorption of statins
anticoagulants ↑  the anticoagulant effectiveness
Ion exchange resins ↓  absorption of statins
colchicine ↑  toxicity of colchicine
glibenclamide ↑  plasma levels of glibenclamide
oral contraceptives ↑  up to 30% in blood hormone levels
Table 4. Other drug that interact with statin
4.4. Recommendations to prevent adverse effects with statin use
Select the dose and type of statin, according to the type of patient cardiovascular risk and
potential adverse effects.
Use moderate intensity therapy if the patient has renal or hepatic dysfunction including
unexplained persistent transaminase elevations, history of muscular disorders or intolerance
to statin use, ALT elevations >3 times the upper limit, concurrent use of medication known
interactions with statin, age greater than 75 years, history of hemorrhagic stroke event, asian
ancestry. This behavior can substantially reduce adverse events with statin use. The use of
simvastatin is not recommended at doses of 80 mg/day because of the risk of toxicity. Liver
function tests should be performed before starting statin therapy, with dose changes with the
change of drug. During treatment should be monitored signs and symptoms of muscle toxicity.
Whenever a statin prescribing or replaced by another is important to analyze the other co-
administered drugs due to the risk of clinically relevant interactions. In the absence of
abnormal liver function and potential interactions with coadministered drugs, statins are all
interchangeable. In the presence of inducing drugs or inhibitors of CYP3A4, fluvastatin,
pravastatin and rosuvastatin are interchangeable. In the presence of inducers or inhibitors of
CYP2C9 drugs, statins are all interchangeable, except fluvastatin. In the presence of drugs
inducing activad or inhibitors of P-gp, fluvastatin and rosuvastatin are interchangeable. In the
presence of inducers or inhibitors of OATP1B1 drugs, is not recommended therapeutic
interchange of pravastatin and rosuvastatin. For all other statins, the exchange must be made
with caution.
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4.5. Analytical monitoring
Monitoring of CK at baseline in patients with or without a history of myopathy, have no solid
evidence. It could only be recommended if the patient has muscle symptoms, weakness or
fatigue. The only test that is fully justified, prior to initiating statin is the measurement of ALT.
The liver function should be measured if the patient is suspected of hepatotoxicity statin use.
With the same level of evidence is regular monitoring of blood glucose, the onset of diabetes
mellitus associated with treatment [21].
4.6. Attitude pain, muscle stiffness, weakness or muscle fatigue statin taker
Clarify if the symptoms actually developed or intensified therapy. If there is a causal relation‐
ship apparent, and muscle symptoms are intolerable, discontinue medication. If rhabdomyol‐
ysis is suspected, measure CK-creatinine and urinalysis. If muscular symptoms are mild or
moderate statin should be discontinued to reassess symptoms and assess whether the patient
has conditions that increase risk of muscle symptoms (hypothyroidism, renal or hepatic
dysfunction, polymyalgia rheumatica, steroid myopathy, vitamin D or primary) myopathies.
If symptoms are resolved and there are no contraindications, restart the same statin at a lower
dose. If symptoms relapse: start another statin at a lower dose and increase slowly. If after 2
months, the symptoms do not improve or CK levels do not decrease, consider alternative
etiologies. If muscle symptoms persist after stopping statin or other clinical condition corre‐
spond to restart therapy [21].
In summary, the adverse events associated with statin therapy are uncommon. Statins are not
associated with cancer risk, but on the contrary there is a greater chance of diabetes. Simvas‐
tatin and pravastatin appear to be safer and better tolerated than other statins [22]. It has not
been able to show that there are real differences between the effects generic statin drug and
reference mark to the modification of the lipid profile, nor in adverse reactions, assessed
according to the elevation of transaminases and CPK [23,24].
5. Conclusions
Atherosclerotic cardiovascular disease is one of the most important public health problems of
our time, both in Europe and in the rest of the world. Consistency of clinical care, incorporating
new evidence and synthesis of recommendations from current practice is common task in
various committees for clinical practice worldwide (Europe-ESC, American-AHA / ACC,
British-NICE, Australian, Canadian...). This has generated discrepancies with the publication
of the latest guidelines of the 2013 AHA/ACC compared to its European namesake 2011 ESC/
EAS. The innovation of greatest impact of the latest guidelines, has been the abandonment of
the therapeutic strategy based on the target values LDL. The individualized strategy (tailored
treatment approach) is recommended identifying four risk groups associated with therapeutic
strategy. Are advised to use statins as well as healthy habits and lifestyle changes for all
patients. The CK should not be measured routinely in patients on statins and there is no reason
to monitor LDL levels.
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